FrancophonIA/ELRC3.0 huggingface dataset:
English: Because Pregabalin Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Pregabalin Mylan on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: What is Pregabalin Mylan and what is it used for?
Estonian: Mis on Pregabalin Mylan ja milleks seda kasutatakse?
English: Studies on the benefits and risks of the active substance in the approved uses have already been carried out with the reference medicine, Lyrica, and do not need to be repeated for Pregabalin Mylan.
Estonian: Võrdlusravimiga Lyrica on juba tehtud toimeaine heakskiidetud kasutamisviiside kasulikkuse ja riski uuringud ning neid ei ole vaja ravimiga Pregabalin Mylan korrata.
English: This is a summary of the European public assessment report (EPAR) for Pregabalin Mylan.
Estonian: See on ravimi Pregabalin Mylan Euroopa avaliku hindamisaruande kokkuvõte.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pregabalin Mylan has been shown to have comparable quality and to be bioequivalent to Lyrica.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Pregabalin Mylan võrreldav kvaliteet ja bioekvivalentsus ravimiga Lyrica.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pregabalin Mylan have been included in the summary of product characteristics and the package leaflet.
Estonian: Ravimi Pregabalin Mylan ohutu ja efektiivse kasutamise soovitused ning ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: For practical information about using Pregabalin Mylan, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Pregabalin Mylani kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: It is not intended to provide practical advice on how to use Pregabalin Mylan.
Estonian: Hindamisaruandes ei anta Pregabalin Mylani kasutamise praktilisi nõuandeid.
English: For more information about treatment with Pregabalin Mylan, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Pregabalin Mylaniga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Therefore, the CHMP's view was that, as for Lyrica, the benefit outweighs the identified risk.
Estonian: Seetõttu on inimravimite komitee arvamusel, et nagu ka Lyrica korral, ületab ravimi Pregabalin Mylan kasulikkus sellega kaasnevad riskid.
English: Pregabalin Mylan is a ‘generic medicine'.
Estonian: Pregabalin Mylan on geneeriline ravim.
English: Pregabalin Mylan contains the active substance pregabalin.
Estonian: Pregabalin Mylan sisaldab toimeainena pregabaliini.
English: Why is Pregabalin Mylan approved?
Estonian: Miks Pregabalin Mylan heaks kiideti?
English: Other information about Pregabalin Mylan
Estonian: Muu teave Pregabalin Mylani kohta
English: How is Pregabalin Mylan used?
Estonian: Kuidas Pregabalin Mylanit kasutatakse?
English: How has Pregabalin Mylan been studied?
Estonian: Kuidas Pregabalin Mylanit uuriti?
English: What are the benefits and risks of Pregabalin Mylan?
Estonian: Milles seisneb Pregabalin Mylani kasulikkus ja mis riskid ravimiga kaasnevad?
English: How does Pregabalin Mylan work?
Estonian: Kuidas Pregabalin Mylan toimib?
English: --1 Live myxoma vectored rabbit haemorrhagic disease (RHD) virus: Strain 009: ≥103.0 and ≤105.8 FFU* Strain MK1899: ≥103.0 and ≤105.8 FFU* *Focus Forming Units
Estonian: --1 Elus müksoomvektoriga küülikute hemorraagilise haiguse (RHD) viirus: tüvi 009: ≥103,0 ja ≤105,8 FFU* tüvi MK1899: ≥103,0 ja ≤105,8 FFU* *Koldeid moodustav ühik
English: EU (MA) number
Estonian: EL (ML) number
English: Lyophilisate: 50 doses, solvent: 10 ml
Estonian: Lüofilisaat: 50 annust, lahusti: 10 ml
English: Solvent: 10 vials
Estonian: Pappkarbis: lahusti: 10 viaali
English: Lyophilisate: 10 vials, In cardboard box:
Estonian: Pappkarbis: lüofilisaat: 10 viaali.
English: The full EPAR for Aclasta can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Aclasta kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: What measures are being taken to ensure the safe and effective use of Aclasta?
Estonian: Mis meetmed võetakse, et tagada Aclasta ohutu ja efektiivne kasutamine?
English: A risk management plan has been developed to ensure that Aclasta is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Aclasta võimalikult ohutu kasutamine.
English: The effect of each infusion lasts for a year or more.
Estonian: Iga infusiooni toime kestab ühe aasta või kauem.
English: Other information about Aclasta:
Estonian: Muu teave Aclasta kohta
English: The European Commission granted a marketing authorisation valid throughout the EU for Aclasta on 15 April 2005.
Estonian: Euroopa Komisjon andis Aclasta müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 15. aprillil
English: Aclasta is given as an infusion lasting at least 15 minutes.
Estonian: Aclastat manustatakse vähemalt 15 minutit kestva infusioonina.
English: The most common side effect with Aclasta (seen in more than 1 patient in 10) is fever.
Estonian: Aclasta kõige sagedam kõrvalnäht (esinenud enam kui 1 patsiendil 10st) on palavik.
English: Most side effects with Aclasta tend to occur within the first three days after infusion, becoming less common with repeated infusions.
Estonian: Enamik Aclasta kõrvalnähte ilmnevad infusioonile järgneva esimese kolme päeva jooksul ning muutuvad korduvate infusioonide järel harvemaks.
English: In these studies, the patients could take other medicines for osteoporosis, but not other bisphosphonates.
Estonian: Kõigis uuringuis võisid patsiendid osteoporoosi vastu kasutada ka teisi ravimeid, kuid mitte teisi bisfosfonaate.
English: The CHMP decided that Aclasta's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Aclasta kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: The patients received one infusion of Aclasta or they took risedronate once a day for two months.
Estonian: Patsientidele tehti kas üks Aclasta infusioon või neile anti risedronaati üks kord ööpäevas kahe kuu jooksul.
English: Using paracetamol or ibuprofen (anti-inflammatory medicines) shortly after Aclasta can reduce symptoms such as fever, muscle pain, influenza (flu)-like symptoms, joint pain and headache in the three days following the infusion.
Estonian: Paratsetamooli või ibuprofeeni (põletikuvastased ravimid) kasutamine lühiajaliselt pärast Aclasta manustamist võib vähendada sümptomeid, nagu palavik, lihasevalu, gripilaadsed sümptomid, liigesevalu ja peavalu infusioonile järgneva kolme päeva jooksul.
English: Gradually, the bones become thin and fragile, and more likely to fracture.
Estonian: Luud muutuvad järk-järgult urbsemaks ja hapramaks ning murduvad kergesti.
English: What is Aclasta?
Estonian: Mis on Aclasta?
English: It is used in patients who are at risk of fractures (broken bones) including those who have recently broken their hip in a minor trauma such as a fall, and in patients whose osteoporosis is linked to long-term treatment with glucocorticoids (a type of steroid).
Estonian: Seda kasutatakse patsientidel, kellel on luumurru risk, sealhulgas patsientidel, kellel on väikese trauma, näiteks kukkumise tagajärjel olnud hiljuti puusamurd, samuti patsientidel, kelle osteoporoos on seotud pikaajalise glükokortikoidraviga (teatud steroidraviga).
English: This leads to less bone loss in osteoporosis and less disease activity in Paget's disease.
Estonian: Selle tulemuseks on luukoe väiksem hävimine osteoporoosi korral ning haiguse väiksem aktiivsus Pageti luuhaiguse korral.
English: Patients must have adequate fluids before and after treatment, and should receive adequate supplements of vitamin D and calcium.
Estonian: Patsiendile tuleb enne ja pärast ravi manustada piisavalt vedelikku ning täiendavalt piisavalt Dvitamiini ja kaltsiumi.
English: In Paget's disease, the bone breaks down more quickly, and when it grows back, it is weaker than normal.
Estonian: Pageti luuhaiguse korral laguneb luukude kiiremini ning kui see uuesti moodustub, on see normaalsest luukoest nõrgem.
English: Osteonecrosis of the jaw (damage to the bones of the jaw, which could lead to pain, sores in the mouth or loosening of teeth) has been reported rarely (seen in between 1 and 10 patients in 10,000).
Estonian: Harva on teatatud ka lõualuu osteonekroosist, millega kaasneb lõualuukoe kahjustus, mis võib põhjustada valu, suuhaavandeid või hammaste loksumist (esinenud 1 kuni 10 patsiendil 10 000st).
English: For the full list of all side effects reported with Aclasta, see the package leaflet.
Estonian: Aclasta kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: This document is a summary of the European Public Assessment Report (EPAR) for Aclasta.
Estonian: See on ravimi Aclasta Euroopa avaliku hindamisaruande kokkuvõte.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Aclasta, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Aclasta omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: Zoledronic acid has also been authorised in the European Union (EU) as Zometa since March 2001 for the prevention of bone complications in patients with cancer that is affecting the bone, and for the treatment of hypercalcaemia (high blood calcium levels) caused by tumours.
Estonian: Soledroonhappele anti märtsis 2001 Euroopa Liidus müügiluba ka ravimina Zometa kasutamiseks luutüsistuste ennetamisel patsientidel, kellel on luid kahjustav vähktõbi, ja kasvajatest tingitud hüperkaltseemia (kaltsiumi liiga suur sisaldus veres) raviks.
English: For osteoporosis, Aclasta has been studied in three main studies.
Estonian: Aclasta kasutamist osteoporoosi ravis uuriti kolmes põhiuuringus.
English: Why has Aclasta been approved?
Estonian: Miks Aclasta heaks kiideti?
English: Patients will also be provided with a reminder card on the risk of osteonecrosis of the jaw, instructing patients to contact their doctor if they experience symptoms.
Estonian: Patsientidele antakse ka meeldetuletuskaart lõualuu osteonekroosi riski kohta, milles patsiente ärgitatakse sümptomite ilmnemisel arsti poole pöörduma.
English: Because zoledronic acid has been authorised in the EU as Zometa for a number of years, the company presented the results of some studies carried out with Zometa, which were taken into account when assessing Aclasta.
Estonian: Et soledroonhappel on ravimina Zometa olnud Euroopa Liidus müügiluba aastaid, esitas ettevõte Aclasta hindamise toetuseks Zometa uuringute tulemusi.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Aclasta.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: In women, osteoporosis is more common after the menopause, when the levels of the female hormone oestrogen fall.
Estonian: Naistel on osteoporoos sagedam pärast menopausi, kui naissuguhormooni östrogeeni sisaldus langeb.
English: For Paget's disease, Aclasta has been compared with risedronate in a total of 357 adults in two studies lasting six months.
Estonian: Pageti luuhaiguse korral võrreldi Aclastat risedronaadiga kokku 357 patsiendil kahes uuringus, mis kestsid kuus kuud.
English: It will also provide an information pack for patients to explain the medicine's side effects, remind them of the need for adequate calcium and vitamin D supplementation, and when patients should contact their doctor.
Estonian: See sisaldab ka patsientide teabepaket, milles selgitatakse ravimi kõrvalnähte, rõhutatakse vajadust võtta kaltsiumi ja D-vitamiini ning antakse soovitusi arsti poole pöördumiseks.
English: There was a 41% risk reduction in hip fractures, when comparing all women taking Aclasta (with or without other osteoporosis medicines) with those taking placebo.
Estonian: Puusamurdude risk vähenes 41%, kui võrrelda kõiki Aclastat (koos teiste osteoporoosi ravimitega või mitte) kasutanud naisi platseebot kasutanud naistega.
English: After six months, around 96% of patients had responded to treatment in the two studies, compared with around 74% of the patients who received risedronate.
Estonian: Kuue kuu möödudes tekkis ravivastus 96%-l mõlemas uuringus kokku osalenud patsientidest.
English: In the treatment of Paget's disease of the bone, Aclasta must only be used by a doctor who has experience in the treatment of the disease.
Estonian: Pageti luuhaiguse raviks võib Aclastat manustada vaid selle haiguse ravis kogenud arst.
English: Aclasta must not be used in patients with severe kidney problems, hypocalcaemia (low blood calcium levels), or in pregnant or breastfeeding women.
Estonian: Aclastat ei tohi kasutada patsiendid, kellel on rasked neeruprobleemid, hüpokaltseemia (kaltsiumivaegus), samuti raseduse ja imetamise ajal.
English: Aclasta is also used to treat Paget's disease of the bone in adults.
Estonian: Aclastat kasutatakse ka Pageti luutõve raviks täiskasvanutel.
English: The third compared one infusion of Aclasta with daily treatment with risedronate (another bisphosphonate) in 833 men and women with osteoporosis caused by glucocorticoids, and looked at the change in the density of the bones in the spine over a year.
Estonian: Kolmandas võrreldi Aclasta ühe infusiooni toimet igapäevase risedronaadiraviga (samuti bisfosfonaat) 833 mehel ja naisel, kelle osteoporoosi oli põhjustanud glükokortikoidravi; uuringus vaadeldi lülisamba luukoe tiheduse muutusi ühe aasta jooksul.
English: The active substance in Aclasta, zoledronic acid, is a bisphosphonate.
Estonian: Aclasta toimeaine soledroonhape on bisfosfonaat.
English: For Paget's disease, only one infusion of Aclasta is usually given, but additional infusions can be considered if the patient's disease comes back.
Estonian: Pageti luuhaigusega patsientidele tehakse ainult üks Aclasta infusioon, kuid haiguse taastudes võib infusioone korrata.
English: The company that makes Aclasta will provide educational packs in each Member State for doctors who prescribe Aclasta for osteoporosis, reminding them how the medicine should be used.
Estonian: Aclasta tootja koostab Aclastat osteoporoosi raviks määravatele liikmesriikide arstidele teabematerjali meeldetuletusega ravimi kasutamise kohta.
English: What is the risk associated with Aclasta?
Estonian: Mis riskid Aclastaga kaasnevad?
English: In the study of elderly women, the risk of fractures in the spine was reduced by 70% in patients taking Aclasta (without any other medicines for osteoporosis) over three years when compared with those taking placebo.
Estonian: Eakate naiste uuring näitas, et võrreldes platseebot kasutanud patsientidega vähenes kolme aasta jooksul lülisambamurdude risk Aclastat (ilma ühegi teise osteoporoosiravimita) kasutanud patsientidel 70% võrra.
English: Patients who have broken their hip should not receive Aclasta any earlier than two weeks after the operation to repair the fracture.
Estonian: Puusamurruga patsientidele ei tohi manustada Aclastat luumurru raviks varem kui kaks nädalat pärast puusamurru operatsiooni.
English: How does Aclasta work?
Estonian: Kuidas Aclasta toimib?
English: The main measure of effectiveness was the number of patients who responded to treatment, defined as blood levels of serum alkaline phosphatase (an enzyme involved in the breakdown of bone) returning to normal or falling at least three-quarters of the way back to normal.
Estonian: Efektiivsuse põhinäitaja oli ravivastusega patsientide arv; ravivastust määratleti kui aluselise fosfataasi (luukoe lagunemises osaleva ensüümi) sisalduse täielikku või kuni 75% võrra normaliseerumist vereseerumis.
English: Aclasta must not be used in people who are hypersensitive (allergic) to zoledronic acid, to other bisphosphonates or to any of the other ingredients.
Estonian: Aclasta ei tohi kasutada patsiendid, kes võivad olla soledroonhappe, teiste bisfosfonaatide või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: This is a disease where the normal process of bone growth is changed.
Estonian: Selle haiguse korral on normaalne luukoe moodustumine häiritud.
English: Aclasta is a solution for infusion (drip) into a vein that contains the active substance zoledronic acid.
Estonian: Aclasta on infusioonilahus (veeni tilgutatav lahus), mis sisaldab toimeainena soledroonhapet.
English: What benefit has Aclasta shown during the studies?
Estonian: Milles seisneb uuringute põhjal Aclasta kasulikkus?
English: The second study compared Aclasta with placebo in 2,127 men and women with osteoporosis who had recently broken their hip, and looked at the number of fractures over up to five years.
Estonian: Teises võrreldi Aclastat platseeboga 2127 osteoporoosiga mehel ja naisel, kellel oli hiljuti olnud puusamurd; uuringus vaadeldi luumurdude arvu viie aasta jooksul.
English: In osteoporosis, Aclasta was more effective than the comparator medicines.
Estonian: Osteoporoosi ravis oli Aclasta võrdlusravimitest efektiivsem.
English: Aclasta should not be used in patients with severe kidney problems.
Estonian: Raske neeruhaigusega patsientidel ei tohi Aclastat kasutada.
English: The first compared Aclasta with placebo (a dummy treatment) in almost 8,000 elderly women with osteoporosis, looking at the number of fractures in the spine and the hip over three years.
Estonian: Esimeses võrreldi Aclasta toimet platseeboga (näiv ravim) ligikaudu 8000 eakal osteoporoosiga naisel; uuringus vaadeldi lülisamba- ja puusamurdude arvu kolme aasta jooksul.
English: In the study of men and women who had broken their hip, 9% of the patients receiving Aclasta had a fracture (92 out of 1,065), compared with
Estonian: Puusamurruga meeste ja naiste uuringus esines uusi luumurde Aclastat saanud patsientidest 9%-l (92 patsienti 1065-st), platseebot saanutest 13%-l (139 patsienti 1062-st).
English: In Paget's disease, Aclasta was more effective than risedronate.
Estonian: Pageti luuhaiguse korral oli Aclasta efektiivsem kui risedronaat.
English: It stops the action of the osteoclasts, the cells in the body that are involved in breaking down the bone tissue.
Estonian: Toimeaine peatab osteoklastide ehk luukoe lagundamisel osalevate rakkude tegevuse.
English: Aclasta is used to treat osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and in men.
Estonian: Aclasta kasutatakse osteoporoosi (luu-urbnemuse) raviks meestel ja menopausijärgses eas naistel.
English: Osteoporosis can also occur in both sexes as a side effect of glucocorticoid treatment.
Estonian: Osteoporoos võib esineda glükokortikoidravi kõrvalnähuna nii naistel kui ka meestel.
English: Aclasta zoledronic acid
Estonian: Aclasta soledroonhape
English: This can be repeated once a year in patients being treated for osteoporosis.
Estonian: Osteoporoosi ravimisel võib infusiooni manustamist korrata üks kord aastas.
English: How is Aclasta used?
Estonian: Kuidas Aclastat kasutatakse?
English: What is Aclasta used for?
Estonian: Milleks Aclastat kasutatakse?
English: The medicine can only be obtained with a prescription.
Estonian: Aclasta on retseptiravim.
English: Finally, Aclasta was more effective than risedronate at increasing spine bone density over a year's treatment in patients taking glucocorticoids.
Estonian: Glükokortikoide kasutanud patsientidel oli ühe aasta jooksul kasutatud Aclasta lülisamba luutiheduse suurendamisel risedronaadist efektiivsem.
English: For more information about treatment with Aclasta, read the Package Leaflet (also part of the EPAR).
Estonian: Ravimi kasutamise üksikasjalik teave on pakendi infolehel, mis on samuti Euroopa avaliku hindamisaruande osa.
English: 2 vials + 1 vial
Estonian: 2 viaali + 1 viaal
English: Solution: 5 ml (30 mg/ml) + Flushing solution 5ml
Estonian: Lahus: 5 ml (30 mg/ml) + loputuslahus 5 ml
English: 150 mg Solution for infusion
Estonian: 150 mg Infusioonilahus Intratserebroventri kulaarne viaal (klaas)
English: This can result in serious vision loss and even blindness.
Estonian: Tagajärjeks võib olla nägemise tugev halvenemine ja isegi pimedaks jäämine.
English: Side effects reported in children are similar to those seen in adults.
Estonian: Laste kohta teatatud kõrvalnähud on sarnased täiskasvanutel täheldatutega.
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Travatan on 27 November 2001.
Estonian: Euroopa Komisjon andis Travatani müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 27. novembril 2001.
English: The full EPAR for Travatan can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Travatani kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: If other eye drops are also being used, they should be given at least 5 minutes apart.
Estonian: Kui silma siserõhu vähendamiseks kasutatakse ka teisi silmatilku, tuleb neid manustada vähemalt 5minutilise vahega.
English: There may also be changes to the patient's eyelashes, including increased length, thickness, colour or number of lashes.
Estonian: Muutused võivad tekkida ka patsiendi ripsmetes, sealhulgas ripsmete pikkuse, tiheduse ja arvu suurenemine või värvuse muutumine.
English: A fourth study also compared the effectiveness of adding Travatan to treatment with timolol (427 patients, six-month duration).
Estonian: Neljandas uuringus võrreldi Travatani efektiivsust lisamisel ravile timolooliga (427 patsienti, kestus 6 kuud).
English: In addition, Travatan was compared with timolol in a fifth main study over 3 months, involving 152 children between 2 months and 18 years of age.
Estonian: Lisaks võrreldi Travatani timolooliga ka viiendas põhiuuringus, mis kestis üle 3 kuu ja milles osales 152 last vanuses 2 kuud kuni 18 aastat.
English: Travatan has been studied in 1,989 adult patients in three main studies, lasting between six and 12 months.
Estonian: Travatani uuriti 1989 täiskasvanud patsiendil kolmes põhiuuringus, mis kestsid 6-12 kuud.
English: The CHMP decided that Travatan's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Travatani kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: It can also be used in children from two months of age who have ocular hypertension or childhood glaucoma.
Estonian: Ravimit tohib kasutada ka vähemalt 2-kuulistel lastel, kellel on okulaarne hüpertensioon või lapseea glaukoom.
English: The dose is one drop of Travatan in the affected eye(s) once a day, preferably in the evening.
Estonian: Annus on üks tilk Travatani haigesse silma või haigetesse silmadesse üks kord ööpäevas, eelistatavalt õhtul.
English: This helps to reduce the pressure inside the eye.
Estonian: See aitab silma siserõhku vähendada.